General Information of Drug (ID: DMI17QR)

Drug Name
LYS006 Drug Info
Synonyms
LYS-006; 1799681-85-8; LTA4H-IN-1; betaS-amino-5-[4-[(5-chloro-3-fluoro-2-pyridinyl)oxy]phenyl]-2H-tetrazole-2-butanoic acid; LYS006; CHEMBL4852381; (3S)-3-amino-4-[5-[4-(5-chloro-3-fluoropyridin-2-yl)oxyphenyl]tetrazol-2-yl]butanoic acid; 59CF90960T; (3~{S})-3-azanyl-4-[5-[4-(5-chloranyl-3-fluoranyl-pyridin-2-yl)oxyphenyl]-1,2,3,4-tetrazol-2-yl]butanoic acid; SCHEMBL16827313; UNII-59CF90960T; GTPL11205; EX-A4286; BDBM50575488; MS-26579; HY-137298; CS-0137600; (S)-3-amino-4-(5-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenyl)-2H-tetrazol-2-yl)butanoic acid; 2H-TETRAZOLE-2-BUTANOIC ACID, .BETA.-AMINO-5-(4-((5-CHLORO-3-FLUORO-2-PYRIDINYL)OXY)PHENYL)-, (.BETA.S)-; 2H-Tetrazole-2-butanoic acid, beta-amino-5-(4-((5-chloro-3-fluoro-2-pyridinyl)oxy)phenyl)-, (betaS)-; RZE
Indication
Disease Entry ICD 11 Status REF
Ulcerative colitis DD71 Phase 2 [1]
Cross-matching ID
PubChem CID
118166560
TTD Drug ID
DMI17QR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bestatin DM8L9D4 Acute myeloid leukaemia 2A60 Approved [3]
Acebilustat DM19UTO Chronic blistering skin disorder ME63.3 Phase 1 [4]
DG051 DM3I0GS Myocardial infarction BA41-BA43 Discontinued in Phase 2 [5]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [6]
JNJ-10392980 DMZH0K8 Discovery agent N.A. Investigative [7]
4-(2-amino-1,3-thiazol-4-yl)phenol DMH5CAQ Discovery agent N.A. Investigative [8]
2-(4-phenoxyphenoxy)ethanamine DM7TBUJ Discovery agent N.A. Investigative [9]
3-(Benzyloxy)Pyridin-2-Amine DM35VEI Discovery agent N.A. Investigative [6]
2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine DMD2QVO Discovery agent N.A. Investigative [10]
2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole DMMYJ3R Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene A-4 hydrolase (LTA4H) TTXZEAJ LKHA4_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04074590) A Randomized, Multi-center, Subject and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis. U.S.National Institutes of Health.
2 Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A(4) Hydrolase. J Med Chem. 2021 Feb 25;64(4):1889-1903.
3 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
8 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
9 Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
10 Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.